20240029884. TECHNIQUES FOR DETECTING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) simplified abstract (BostonGene Corporation)
Contents
TECHNIQUES FOR DETECTING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)
Organization Name
Inventor(s)
Nikita Kotlov of Waltham MA (US)
Aleksei Shevkoplias of Yerevan (AM)
Alexandra Melnikova of Yerevan (AM)
Alexander Bagaev of Waltham MA (US)
Mariia Guryleva of St. Petersburg (RU)
TECHNIQUES FOR DETECTING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240029884 titled 'TECHNIQUES FOR DETECTING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)
Simplified Explanation
The abstract describes techniques for determining whether a biological sample obtained from a subject contains cells with homologous recombination deficiency (HRD). The techniques involve obtaining data about segments of the subject's genome and identifying two subsets of these segments. The first subset includes segments associated with at least one chromosome arm of the genome and having a common copy number. The second subset includes segments with a copy number different from the common copy number and a length that satisfies a predetermined criterion. The proportion of segments in the second subset to the number of chromosome arms is determined to determine if the sample includes cells with HRD.
- Techniques for determining HRD in a biological sample obtained from a subject
- Obtain data about segments of the subject's genome
- Identify a first subset of segments associated with at least one chromosome arm and having a common copy number
- Identify a second subset of segments with a different copy number and a length that meets a predetermined criterion
- Determine the proportion of segments in the second subset to the number of chromosome arms
- Determine if the sample includes cells with HRD based on the determined proportion
Potential applications of this technology:
- Identifying patients who may benefit from targeted therapies for HRD-related conditions
- Assessing the effectiveness of HRD-targeted treatments in clinical trials
Problems solved by this technology:
- Accurately identifying cells with HRD in a biological sample
- Providing a non-invasive method for determining HRD status in patients
Benefits of this technology:
- Enables personalized medicine by identifying patients who may respond to HRD-targeted therapies
- Facilitates the development of more effective treatments for HRD-related conditions
Original Abstract Submitted
techniques for determining whether a sample obtained from a subject includes cells having homologous recombination deficiency (hrd). the techniques include: obtaining data about segments of the subject's genome; identifying a first subset of the segments, the first subset including segments associated with at least one chromosome arm of the genome and having a common copy number; identifying a second subset of the segments, each of the segments of the second subset having (i) a respective copy number different from the common copy number and (ii) a respective length that satisfies a predetermined length criterion; determining a proportion of a number of segments in the second subset to a number of chromosome arms of the at least one chromosome arm; and determining, based on the determined proportion, whether the biological sample includes cells having hrd.
